‘Risk-sharing’ as a tool for enabling fast access to COVID-19 vaccines
In a time of global pandemic, traditional vaccine procurement schemes are not fit for purpose and need to adapt to allow both governments and manufacturers the...
Anthony Barron is a Principal in the Life Sciences Practice of Charles River Associates based in Brussels. He has been working on European and international pharmaceuticals policy issues for more than 10 years.
Anthony regularly advises clients on health financing and pharmaceutical market access policy issues and has conducted a number of research projects on access to medicines and industrial policy in the pharmaceutical sector in Europe for EFPIA, PhRMA, IFPMA, EuropaBio, and the European Commission. This includes research regarding barriers to access to medicines, pharmaceutical pricing policies, health technology assessments, the value of healthcare biotech, as well as recent market access projects such as on AdaptSmart or evaluating the impact of Brexit on the life sciences sector.